Hepatitis C - alpha interferon and ribavirin (replaced by TA75)
The clinical and cost effectiveness of pegylated interferon alpha 2a and alpha 2b for hepatitis C
Summary
This guidance has now been reviewed and extended by Hepatitis C - pegylated interferons, ribavarin and alfa interferon.
Guidance documents
Implementing this guidance
Other information
About this guidance
Technology appraisals TA14
Issued: October 2000
How this guidance was produced